Atlas Trials

Grade III Neuroendocrine Carcinoma

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Grade III Neuroendocrine Carcinoma

RecordFirmDate
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (NCT03728361)Dwight Owen2018-12-31

Track Grade III Neuroendocrine Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.